MarketCapExport financials
Novartis AG (NVS)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Novartis AG Income Statement 2025-2011 | NVS
Brief overview of financial performance at Novartis AG
The figures are compared over a five-year interval. According to figures from Novartis AG, revenue changed from 50.4 billion dollars to 49.9 billion dollars over five years. Across the full period, sales moved by −1%; the average annual rate was −0.2%. The scale of the core business was largely unchanged.
Gross profit changed from $33 billion to $34.8 billion (+5.4%). The gross margin was 65.5% at the start and 69.7% at the end. The business retained more gross profit from each unit of revenue.
EBITDA was 14.4 billion dollars at the beginning and 10.2 billion dollars at the end of the period (−29.7%). Changes in revenue did not translate into comparable EBITDA performance. EBITDA margin was 28.7% at the start and 20.3% at the end. The business retained less EBITDA from each unit of revenue.
Net profit was 17.8 billion dollars at the start and 8.1 billion dollars at the end. The final result developed less favorably than the core business.
Over the period, capitalization shifted from 168 billion dollars to 198 billion dollars (+18.2%). Investor expectations increased faster than reported performance.
Financial takeaway
The financial trajectory is weak and requires a cautious interpretation. Key strengths include better sales economics. The most visible risks are a softer top-line trend, weaker operating efficiency and declining net profitability. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Novartis AG
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
316 B | 214 B | 210 B | 221 B | 195 B | 198 B | 201 B | 164 B | 164 B | 154 B | 168 B | 212 B | 175 B | 148 B | 116 B |
Shares |
1.94 B | 2.02 B | 2.08 B | 2.18 B | 2.24 B | 2.28 B | 2.29 B | 2.32 B | 2.35 B | 2.38 B | 2.4 B | 2.43 B | 2.44 B | 2.42 B | 2.38 B |
Historical Prices |
163 | 106 | 101 | 101 | 86.9 | 87.2 | 87.9 | 70.6 | 70.1 | 55.3 | 55.9 | 68 | 53.4 | 44.1 | 33.8 |
Net Income |
14 B | 11.9 B | 14.9 B | 6.96 B | 24 B | 8.07 B | 11.7 B | 12.6 B | 7.7 B | 6.71 B | 17.8 B | 10.2 B | 9.18 B | 9.5 B | 9.11 B |
Revenue |
- | - | - | - | - | 49.9 B | 48.7 B | 53.2 B | 50.1 B | 49.4 B | 50.4 B | 53.6 B | 58.8 B | 57.6 B | 59.4 B |
Cost of Revenue |
13.7 B | 12.8 B | 12.5 B | 11.6 B | 15.9 B | 15.1 B | 14.4 B | 14.5 B | 13.6 B | 17.5 B | - | - | - | - | - |
Gross Profit |
43 B | 38.9 B | 34.2 B | 31.9 B | 32.2 B | 34.8 B | 34.3 B | 31.6 B | 29.8 B | 31.9 B | 33 B | 36.3 B | 39.2 B | 38.8 B | 40.4 B |
Operating Income |
17.6 B | 14.5 B | 9.77 B | 7.95 B | 11.7 B | 10.2 B | 9.09 B | 8.4 B | 8.7 B | 8.27 B | - | - | - | - | - |
Interest Expense |
1.14 B | 1.01 B | 855 M | 800 M | 787 M | 869 M | 850 M | 932 M | 750 M | 707 M | - | - | - | - | - |
EBITDA |
17.6 B | 14.5 B | 9.77 B | 7.95 B | 11.7 B | 10.2 B | 9.09 B | 8.4 B | 8.7 B | 14.3 B | 14.4 B | 15.8 B | 15.8 B | 16.4 B | 16.8 B |
Operating Expenses |
- | - | - | - | - | 24.6 B | 25.2 B | 26.6 B | 24.3 B | 23.6 B | 24 B | 25.2 B | 28.3 B | 27.3 B | 29.4 B |
General and Administrative Expenses |
13.2 B | 12.6 B | 12.5 B | 12.2 B | 14.9 B | - | 14.4 B | 16.5 B | 2.14 B | 2.19 B | 2.48 B | 2.62 B | 3.06 B | 2.94 B | 2.97 B |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Novartis AG
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
1.94 B | 1.95 B | 2.02 B | 2.03 B | 2.08 B | 2.08 B | - | - | 2.21 B | - | - | - | 2.26 B | - | - | - | 2.3 B | - | - | - | 2.33 B | - | - | - | 2.35 B | - | - | - | 2.37 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
14 B | 4.02 B | 11.9 B | 3.25 B | 14.9 B | 2.32 B | - | - | 1.7 B | - | - | - | 2.9 B | - | - | - | 1.87 B | - | - | - | 6.8 B | - | - | - | 7.77 B | - | - | - | 1.98 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
13.7 B | 3.32 B | 12.8 B | 3.17 B | 12.5 B | 4.34 B | - | - | 3.75 B | - | - | - | 3.91 B | - | - | - | 3.43 B | - | - | - | 3.41 B | - | - | - | 3.56 B | - | - | - | 4.26 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
43 B | 11.5 B | 38.9 B | 9.7 B | 34.2 B | 9.6 B | - | - | 9.33 B | - | - | - | 9.38 B | - | - | - | 8.19 B | - | - | - | 8.62 B | - | - | - | 8.1 B | - | - | - | 8.24 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
17.6 B | 4.86 B | 14.5 B | 4.01 B | 9.77 B | 2.92 B | - | - | 2.23 B | - | - | - | 3.48 B | - | - | - | 2.35 B | - | - | - | 2.66 B | - | - | - | 2.43 B | - | - | - | 2.28 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
1.14 B | 289 M | 1.01 B | 246 M | 855 M | 224 M | - | - | 202 M | - | - | - | 201 M | - | - | - | 220 M | - | - | - | 205 M | - | - | - | 237 M | - | - | - | 192 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
17.6 B | 4.86 B | 14.5 B | 4.01 B | 9.77 B | 2.92 B | - | - | 2.23 B | - | - | - | 3.48 B | - | - | - | 2.35 B | - | - | - | 2.66 B | - | - | - | 2.43 B | - | - | - | 2.28 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
13.2 B | 3.44 B | 12.6 B | 3.09 B | 12.5 B | 3.69 B | - | - | 3.58 B | - | - | - | 3.75 B | - | - | - | 3.37 B | - | - | - | 3.58 B | - | - | - | 3.5 B | - | - | - | 3.81 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Novartis AG (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Russia
USA
Canada
Niderland
France
Israel
Australia
Danmark
Irlanda
